Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine"

Pharmacoeconomics. 2022 Oct;40(10):1011-1012. doi: 10.1007/s40273-022-01184-0. Epub 2022 Sep 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aged
  • Aged, 80 and over
  • Belgium
  • Cost-Benefit Analysis
  • Herpes Zoster Vaccine*
  • Herpes Zoster* / prevention & control
  • Humans
  • Middle Aged
  • Vaccines, Attenuated
  • Vaccines, Subunit

Substances

  • Herpes Zoster Vaccine
  • Vaccines, Attenuated
  • Vaccines, Subunit